Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00704782

Enrollment

Registered

2008-06-25

Start date

2008-04-30

Completion date

2010-08-31

Last updated

2015-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.

Interventions

DRUGdimebon

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Alzheimer's disease * On donepezil (Aricept) * Caregiver who cares for the patient at least 5 days per week

Exclusion criteria

* Unstable medical illnesses or significant hepatic or renal disease * Other primary psychiatric or neurological disorders

Design outcomes

Primary

Measure	Time frame
To assess the safety of Dimebon in combination with donepezil (Aricept)	week 6, 9, 12, 26 and every 13 weeks thereafter until study discontinuation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026